EML4–ALK translocation may be associated with resistance to EGFR-TKI, and EGFR signaling may contribute to resistance to ALK inhibitor in EML4–ALK-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.